Full text is available at the source.
Boosting Oral Chemotherapy Efficacy and Ameliorating Intestinal Dysbiosis via a Microfluidic-Engineered RGD-Targeted Nanoplatform against Breast Cancer
Improving Oral Chemotherapy and Restoring Gut Balance with a Targeted Nanoparticle System for Breast Cancer
AI simplified
Abstract
Microfluidics-prepared RGD-modified solid lipid nanoparticles (MF-SLNs) demonstrated a particle size of approximately 120 nm and high encapsulation efficiency (over 80%).
- MF-SLNs showed a stable zeta potential of approximately 20 mV.
- The particle size distribution indicated improved homogeneity with a polydispersity index (PDI) of 0.073.
- Doxorubicin (DOX) was released from MF-SLNs in a slow and sustained manner, suggesting potential for controlled delivery in the gastrointestinal tract.
- In vitro studies revealed significantly enhanced transcellular transport of DOX across the FAE monolayer and increased uptake by MDA-MB-231 breast cancer cells.
- Flow cytometry analysis indicated a higher percentage of apoptotic MDA-MB-231 cells following MF-SLNs treatment.
- In vivo studies in nude mice showed enhanced tumor inhibition and improved survival rates, alongside an increase in beneficial gut bacteria.
AI simplified